WO2000026215A1 - Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine - Google Patents
Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine Download PDFInfo
- Publication number
- WO2000026215A1 WO2000026215A1 PCT/US1999/025080 US9925080W WO0026215A1 WO 2000026215 A1 WO2000026215 A1 WO 2000026215A1 US 9925080 W US9925080 W US 9925080W WO 0026215 A1 WO0026215 A1 WO 0026215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mol
- triazole
- methyl
- dimethylaminomethyl
- formyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention is directed to the compound 4-N,N-dimethyl- aminomethyl-5-formyl-l,2,3-triazole which is a valuable intermediate in the preparation of phamaceutical compounds.
- the present invention further relates to processes for the preparation of 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)- 4-(5-(dimethyl-amino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fiuorophenyl)- morpholine which is useful as a therapeutic agent, in particular as a potent and selective substance P (or neurokinin-1) receptor antagonist.
- Substance P antagonists have potential for use in the treatment of inflammatory diseases, emesis, depresssion, anxiety, and other neuropsychiatric diseases, including bipolar disorder and schizophrenia.
- the present invention is directed to a novel convergent process for the preparation of 2-(R)-(l-(R)-(3, 5-bis(trifluoro-methyl)phenyl)-ethoxy)-4-(5- (dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine.
- This compound is a substance P (neurokinin-1) receptor antagonists which is useful in e.g., inflammatory diseases, emesis, depresssion, anxiety, and other neuropsychiatric diseases, including bipolar disorder and schizophrenia.
- the present invention is directed to the compound 4-N,N-dimethylaminomethyl-5- formyl-l,2,3-triazole which is a valuable intermediate for the preparation of 2-(R)-(l- (R)-(3,5-bis(trifluoro-methyl)phenyl)-ethoxy)-4-(5-(dimethylamino)methyl-l,2,3- triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine.
- the present invention is directed to convergent processes for the preparation of 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-4-(5- (dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)-mo ⁇ holine.
- the present invention accordingly provides a convenient, efficient process which utilizes a one-step reductive amination with 4-N,N- dimethylaminomethyl-5-formyl-l,2,3-triazole that conveniently produces 2-(R)-(l- (R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-4-(5-(dimethylamino)-methyl-l,2,3- triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)-morpholine and avoids the need for multiple steps or high temperature cyclization.
- a process for the preparation of 2-(R)-(l-(R)-(3,5-bis(trifluoro-methyl)phenyl)-ethoxy)- 4-(5-(dimethylamino)methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)- mo ⁇ holine which comprises: contacting 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-3- (S)-(4-fluorophenyl)morpholine with 4-N,N-dimethylamino-methyl-5-formyl-l ,2,3- triazole in an organic solvent in the presence of a reducing agent; to give 2-(R)-( 1 -(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5- (dimethylamino)methyl-
- Suitable reducing agents of use in the above reaction include: sodium triacetoxyborohydride; borane-triethylamine complex; borane-trimethylamine complex; sodium borohydride; sodium cyanoborohydride; borane in the presence of an amine base such as triethylamine; borane-t-butylamine complex; borane-N,N- diethylamine complex; borane-N,N-diisopropylethylamine complex; borane- dimethylamine complex; borane-methylsulfide complex; borane-mo ⁇ holine complex; borane-pyridine complex; borane-tetrahydrofuran complex; lithium aluminum hydride; lithium borohydride; lithium triethoxy-aluminum hydride; lithium trimethoxyaluminum hydride; catalytic hydro genation in the presence of metal or organometalic catalysis; and the like.
- an amine base such as triethyl
- Preferred reducing agents include: sodium triacetoxyborohydride; borane-triethylamine complex; and borane-trimethylamine complex.
- Suitable organic solvents of use in the above reaction include an organic solvent selected from the group consisting of: toluene; dimethylformamide; dimethylacetamide; xylene (including o-xylene, m-xylene, p-xylene, and mixtures thereof); benzene; petroleum ether; hexane; heptane; cumene; mesitylene; diethyl ether; tetrahydrofuran; digylme (2-methoxy-ethyl ether); methyl-t-butyl ether; a chlorinated hydrocarbon such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene, ortho-dichlorobenzene; and the like; and mixtures thereof.
- the organic solvent comprises a solvent which is selected from toluene, dimethylformamide, and mixtures therof. In a more preferred embodiment, the organic solvent comprises a solvent which is selected from dimethylformamide and dimethylacetamide.
- Other ingredients may be present in the reaction mixture, for example, to facilite the preparation of the product or to monitor the progress of the reaction.
- the above reaction is effected in an organic solvent which comprises dimethylacetamide in the presence of sodium triacetoxyborohydride.
- a suitable temperature for this reaction is in the range of about 0- 100°C, preferably about 20-40°C, and most preferably at room temperature.
- the 2-(R)-(l -(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-3- (S)-(4-fluorophenyl)mo ⁇ holine of use in the above reaction is in the form of its toluenesulfonate salt.
- the present invention is directed to the compound 4-N,N-dimethylaminomethyl-5-formyl-l,2,3-triazole which has the following structure:
- Preferred salts of 4-N,N-dimethylaminomethyl-5-formyl- 1,2,3- triazole are acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like.
- a preferred salt form of 4-N,N-dimethylaminomethyl-5-formyl-l,2,3-triazole is the trifluoroacetic acid salt.
- This compound is a valuable intermediate for the preparation of 2-(R)- (l-(R)-(3,5-bis(trifluoro-methyl)phenyl)-ethoxy)-4-(5-(dimethyl-amino)methyl-l,2,3- triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)mo ⁇ holine.
- the strong base is, for example, an organomagnesium halide such as ethylmagnesium chloride, ethylmagnesium bromide or methylmagnesium chloride, or an organolitium reagent such as n- butyllithium, sec-butyllithium, t-butyllithium, and preferably n-butyllithium.
- an organomagnesium halide such as ethylmagnesium chloride, ethylmagnesium bromide or methylmagnesium chloride
- an organolitium reagent such as n- butyllithium, sec-butyllithium, t-butyllithium, and preferably n-butyllithium.
- Suitable organic solvents of use in step (a) include an organic solvent selected from the group consisting of: diethyl ether; tetrahydrofuran; digylme (2-methoxy-ethyl ether); methyl-t-butyl ether; toluene; dimethylformamide; xylene (including o-xylene, m- xylene, p-xylene, and mixtures thereof); benzene; petroleum ether; hexane; heptane; cumene; mesitylene; and the like; and mixtures thereof.
- the organic solvent comprises tetrahydrofuran.
- a suitable temperature for step (a) is in the range of about -80 to 20°C, preferably about -40 to 0°C, and most preferably about -25 to -15°C.
- the N-methylformanilide is preferably added directly to the reaction mixture and preferably the temperature of the reaction is maintained at about -40 to 0°C and then the reaction mixture is allowed to warm to room temperature.
- appropriate strong acids include: trifluoroacetic acid; methanesulfonic acid; hydrochloric acid; hydrogen chloride gas; hydrogen bromide; hydrogen iodide; trifluoromethane-sulfonic acid; camphorsulfonic acid; sulfuric acid; phosphoric acid; and an arylsulfonic acid, such as benzenesulfonic acid, p-toluenesulfonic acid, and p-chlorobenzenesulfonic acid.
- Preferred strong acids include: trifluoroacetic acid; methanesulfonic acid; camphorsulfonic acid; benzenesulfonic acid, p-toluenesulfonic acid; and p-chlorobenzenesulfonic acid.
- the most preferred strong acid is trifluoracetic acid.
- the temperature of the reaction mixture is preferably kept below about -30.
- the reaction mixture is preferably added to a solution of sodium azide in a solvent such as dimethylformamide, dimethylsulfoxide, dimethoxyethane or dioxane, which may further comprise water.
- a solvent such as dimethylformamide, dimethylsulfoxide, dimethoxyethane or dioxane, which may further comprise water.
- the preparation of the desired compound with the process of the present invention may be carried out in sequential or convergent synthetic routes. It is noted that in some cases the order of carrying out the subject reactions may be varied to facilitate the reaction or to avoid unwanted reaction products. In general, the process of the present invention is conducted in a convergent manner as presented herein.
- NMR spectra were run in CDCI3 and the H and ⁇ C spectra were measured at 250 and 62.9 MHz.
- the proton spectra were run with a 10s delay between pulses for the wt% assay.
- Toluene was dried to less than 150 ⁇ g/mL water (by Karl Fisher titration) with 3A sieves. Standard inert atmosphere techniques were used for the reaction and work-up.
- N-Methylformanilide 27.05 g or 24.7 mL 0.20 mol 135.17
- Trifluoroacetic acid 22.80 g or 15.4 mL 0.20 mol 114.02
- reaction mixture was white pasty (but stirrable) due to the aggregates of the acetylide at high concentration.
- N-Methylformanilide (27.05 g, 24.7 mL, 0.2 mol) was added in one portion and the reaction mixture was allowed to warm to room temperature over ca. 15 minutes and further aged at this temperature for 30 minutes. The addition of N- Methylformanilide wasn't exothermic at -20 °C. The reaction becomes clear homogeneous (slightly yellow) at around 0°C.
- reaction mixture was then cooled over a dry ice-acetone bath and trifluoroacetic acid TFA (22.80 g, 15.4 mL, 0.2 mol) was added over ca. 10 minutes maintaining the temperature below -30 °C.
- TFA trifluoroacetic acid
- the resulting acetylenic aldehyde was not stable for more than 1-2 hours at -30 °C (more stable at lower temperature).
- the reaction mixture was yellow and would turn to dark brown upon decomposition of the aldehyde. Crude acetylenic aldehyde must be quenched into sodium azide within 1 to 2 hours.
- reaction mixture (kept below -30 °C) was then added to a DMF solution (500 mL) containing sodium azide (12.35 g, 0.19 mol) and water (25 mL) at room temperature over ca. 15 minutes. Final temperature of the batch was -18 °C. The solution was orange-red with a pH -d2. At this stage, the solution is stable for several days at room temperature.
- the reaction mixture was diluted with water (200 mL) and extracted with MTBE (3 x 200 mL).
- the aqueous solution (2.5/1 DMF/water) was pH adjusted to 8.5 with aqueous HCl (12 ⁇ , ca. 10 mL).
- Assay yield was 95% (based on limiting reagent sodium azide, 27.7 g assay of heterocycle, 0.18 mol).
- ⁇ -methylaniline byproduct and non-reacted ⁇ -methylformanilide are extracted in the MTBE layer.
- the heterocycle remains into the aqueous along with inorganic salts and was >98 A% (at 260 nm).
- the product was isolated by first using about 6 eq. of strong acidic ion exchange resin (eq.
- Metachem inertsil ODS-3 (250x4.6); 1.0 mL/min.; detection at 220 and 260 nm; HP 1100; A: H 2 O (buffered to pH 7); B: Acetonitrile. - 99% A at 0.0 min; 90% A at 10.0 min; 30% A at 20.0 min.
- NaN 3 2.85 min (does not abosb @ 260 nm) 4-N,N-dimethylaminomethyl-5-formyl-l,2,3-triazole : 6.75 min
- DMF 7.85 min (does not abosb @ 260 nm)
- N-methylformanilide 19.85 min N-methylaniline : 22.55 min
- N-Methylformanilide (32.4 g, 29.6 mL, 0.24 mol) was added at room temperature over ca. 10 minutes. The reaction mixture was aged for 60 minutes. The addition was exothermic and was controlled by cooling.
- sodium azide (12.35 g, 0.19 mol) was dissolved in DMSO (400 mL) and water (20 mL). The solution was stirred vigorously while the magnesium acetylide mixture was added at 20-25 °C over 15-30 minutes. The reaction was exothermic and was controlled by cooling. The final temperature of the reaction mixture was -20 °C. The solution was yellowish and hazy due to the magnesium salts. The solution was stable for several days at room temperature.
- the reaction mixture was pH adjusted with aqueous hydrochloric acid (1.0 M) to pH 7.0 - 7.5 and diluted with ethyl acetate (200 mL). The layers are separated.
- the assay yield of 1 -dimethylamino-2-propyne was 90% based on the acetylene and 95% based on sodium azide (27.75 g assay of heterocycle, 0.18 mol). About 90% of N-methylaniline byproduct and non-reacted ⁇ -methylformanilide are extracted in the ethyl acetate layer.
- the aqueous solution was loaded onto the ion exchange resin column (strongly acidic resin Dowex ® 50 W X8-100; 1.7 meq/mL wet, 5 equiv, 1.0 mol, 590 mL) at a flow rate of 4-5 bed volumes per hour.
- the Dowex ® 50 W X8-100 must be properly regenerated prior to use.
- the resin was then washed with three bed volumes of deionized water (1.8 L) at a flow rate of 4-5 bed volumes per hour to remove the DMSO.
- the wash solution on the resin was displaced with one bed volume of a mixture of acetonitrile/water/triethylamine (6:3:1). The flow was stopped and the column was aged for 16 hours.
- the heterocycle was still on the resin.
- the aging allows equilibration reducing the volume of base wash.
- the first bed volume was collected and two additional bed volumes are eluted over ca. one hour providing a 95% assay recovery of the heterocycle (26.4 assay g, 0.171 mol).
- the combined fractions are concentrated to 100 mL.
- Isopropyl alcohol 600 mL was added and the mixture was concentrated to 100 mL. This procedure was repeated until the level of water and triethylamine are reduced to ⁇ 1 V%.
- the product crystallizes during the solvent switch.
- the volume was adjusted to -250 mL.
- the triazole aldehyde was filtered, washed with isopropyl alcohol (-40 mL) and dried at 40 °C under vacuum with a nitrogen stream affording 25 g of pure compound (>99 wt%) in an overall 80% isolated yield (based on 1 -dimethylamino-2-propyne).
- EtMgCl 2.0 M, 110.0 mL, 0.22 mol
- the reaction mixture was aged for 2 hours.
- N-Methylformanilide 27.05 g, 24.7 mL, 0.24 mol was added at room temperature over ca. 10 minutes and the mixture was aged for 60 minutes.
- the additions of EtMgCl and N-Methylformanilide are slightly exothermic and are controlled by cooling.
- the solution of the magnesium acetylide was added to a vigorously stirred solution of sodium azide (12.35 g, 0.19 mol) in DMSO (400 mL) and water (20 mL) at 20-25 °C over 15-30 minutes.
- the reaction was exothermic and was controlled by cooling.
- the reaction mixture was yellow and hazy (magnesium salts).
- the product in the reaction mixture was stable for several days at room temperature.
- the reaction mixture was pH adjusted with aqueous HCl (1.0 M) until pH 7.0 to 7.5.
- the solution was washed with ethyl acetate (200 mL). About 90% of N-methylaniline byproduct and unreacted ⁇ -methylformanilide are extracted into the ethyl acetate.
- the assay yield was 90% based on l-dimethylamino-2-propyne and 95% based on sodium azide (27.75 g assay of heterocycle, 0.18 mol). No azide was detected by assay (LOD ⁇ 50 ppm).
- the crude reaction mixture was loaded onto the strongly acidic resin Dowex® 50 W X8-100 (1.7 meq/mL wet, 5 equiv, 600 mL) at a flow rate of 4-5 bed volumes per hour.
- the Dowex® 50 W X8 must be properly generated prior to use.
- the bed was washed with 1.5 bed volumes of 90% methanol/water to remove any monomer and other organic soluble impurities.
- the procedure for 1 L of resin follows: Slurry one liter of Dowex® 50W resin in water, transfer into a suitable column and drain the water to the top of the bed. The bed was washed with 90% methanol/water (1.5 L) at a flow rate of- 25 minutes per bed volume (1 L). One bed volume of water (1 L) was used to rinse the column. A 1 N NaOH solution (3 L) was passed through the column, followed by 1 bed volume of water (1 L) as a rinse. The column was returned to the acid cycle with one bed volume of 1 N HCl (3 L).
- the product was then eluted with a mixture of acetonitrile:water: triethylamine (6:3:1). After 1 bed volume (-600 mL) was added to the column displacing the water wash, the flow was stopped and the column was equilibrated for 1-2 h. Any breakthrough during the solvent switch can be recycled back to the column. At this stage, the product was on the resin. The age allows equilibration reducing the volume of base wash. An additional 1.5 bed volumes (1.2 L) are eluted over -1 h providing 97% assay recovery of the heterocycle (26.4 assay g, 0.171 mol). The total elution volume was 2.5 bed volumes. Only 1.5 bed volumes are collected leaving one bed volume on the column.
- N-Methylformanilide (892 g, 813 mL, 6.60 mol) was then added over 20 min while maintaining the reaction temperature at 20-25 °C. The resulting clear yellow-to-green mixture was aged at room temperature for 1 h. The additions of EtMgCl and N-methylformanilide are slightly exothermic. The temperature was controlled by cooling the reaction mixture. During the Grignard addition, ethane was produced (ca. 125 L).
- the reaction mixture was transferred into a vigorously stirred DMSO solution (11.0 L) containing sodium azide (339.7 g, 5.22 mol) and water (330 mL, 18.3 mol) over 30 min while maintaining the temperature between 15 °C and 25 °C.
- the 12-L flask was rinsed with THF (0.4 L). The reaction was exothermic and was controlled by cooling the reaction mixture.
- a 50 L flask was used since the final volume after dilution with toluene and Aliquat® was - 40 L.
- Assay yield (763 g assay of heterocycle, 4.95 mol) was -90% based on 1 -dimethylamino-2-propyne and -95% based on sodium azide.
- the level of residual sodium azide was assayed at ⁇ 30 ppm.
- the reaction mixture was yellow-orange and hazy due to magnesium salts.
- the pH of the mixture was 9.7.
- the final aqueous layer was slightly gelatinous due to the suspended magnesium salts.
- the pH was 9.7.
- ⁇ 94% of the product (- 715 assay g of triazole aldehyde, 4.65 mol) has been extracted into the combined organic layers.
- the combined organic layers also contain - 35 A% of DMSO, as compared to the triazole aldehyde, Aliquat® 336, the N-methylaniline byproduct and excess of N- methylformanilide.
- the combined organic layers are washed with water (6.0 L) to remove the DMSO. Less than 1% of triazole aldehyde was extracted into the aqueous layer (ca. 0.6%).
- the organic layer contains ca. 3 A% of DMSO.
- the resulting combined organic layer was washed with water (4.5 L) containing glacial acetic acid (630 mL, 11.0 mol) to release the triazole aldehyde.
- the layers are separated and the organic layer was washed once again with water (2.0 L).
- the two extractions recover 95% of the triazole aldehyde (85% in first one and 10% in second one).
- the N-methylaniline byproduct and the excess N- methylformanilide remain in the organic layer.
- an 86% overall recovery ⁇ 660 assay g, 4.25 mol
- Glacial acetic acid 630 mL 11.0 mol 60.05 d 1.049
- DMSO/THF from Example 4 was alternatively treated as follows: To the reaction mixture was added Aliquat® 336 (6.67 kg, 7.5 L, 16.5 mol) and toluene (11.0 L). The mixture was yellow-orange in color and hazy due to magnesium salts. This mixture was aged under nitrogen for 2 h. The salts are removed by filtration through a pad of solka-floc (3000 mL; - 3 inches in a 6-L sintered-glass funnel). The filtration removes the sodium chloride formed by the displacement of the Aliquot chloride with the sodium salt of the triazole. This leaves the Aliquot as a soluble salt of the triazole in toluene. Filtration of the mixture takes - 1.5 h.
- the pad of solka-floc was rinsed with toluene (3.5 L).
- the resulting hazy-yellow filtrate was transferred into an extractor and diluted with water (6.0 L). The mixture separates into two phases. The layers are well-mixed and separated. The resulting aqueous layer was slightly gelatinous due to the magnesium salts.
- the pH was 9.7. At this stage -89% of product (-680 assay g, 4.40 mol) has been extracted.
- the toluene layer contains the triazole aldehyde along with -35 A% of DMSO
- the organic layer was washed with water (6.0 L) to remove the DMSO.
- the toluene layer contains - 3 A% of DMSO. Less than 1% of the triazole aldehyde was lost in the aqueous layer ( ⁇ 0.6%).
- the organic layer was washed with water (4.5 L) containing glacial acetic acid (630 mL, 11.0 mol) to release the triazole aldehyde.
- the layers are separated and the organic layer was washed with water (2.0 L). These two extractions recover 94% of the triazole aldehyde (85% in the first and 9% in the second).
- the N-methylaniline byproduct and excess N-methylformanilide remain in the organic layer.
- N-Methylformanilide (51.1 g, 46.7 mL, 0.378 mol) was then added over ca. 20 minutes while maintaining the reaction temperature between +20 and +25 °C.
- the resulting yellow-green (clear homogeneous) mixture was aged at room temperature for 1 hour.
- the additions of EtMgCl and N-methylformanilide are slightly exothermic.
- ethane was produced (ca. 7 L).
- the reaction mixture was added into a vigorously stirred solution of
- DMSO 500 mL containing sodium azide (19.5 g, 0.3 mol) and water (8.1 mL, 0.45 mol) over 30 minutes while maintaining the temperature between +15 °C and +25 °C.
- the reaction was exothermic and was controlled by cooling the reaction mixture.
- the final temperature of the batch was ca. +20 °C.
- the assay yield was 91% based on 1- dimethylamino-2 -propyne and 96% based on sodium azide (44.2 g assay of heterocycle, 0.287 mol).
- the level of remaining sodium azide was assayed at ⁇ 30 ppm.
- the reaction mixture was yellow-orange and hazy and the pH was 9.7.
- the resulting yellow slurry was filtered to afford the dimer adduct as a white solid, which was washed with DMSO (60 mL) and ethyl acetate (150 mL), and dried at 40 °C under vacuum with a nitrogen stream for 16 hours to afford 62.1 g of product (95 A%, ca. 87 wt%) as a white solid.
- the isolated yield was 74.5% based on 1 -dimethylamino-2-propyne and 78% based on sodium azide (54.0 g assay of dimer, 0.117 mol). The filtration was fast.
- the solubility of the product in the filtrate was ca.lO g/L as triazole-aldehyde equivalent, which represents a yield loss of 18%.
- the pH of filtrate was 10.3.
- the dimer was pure.
- the low wt% (87 wt%) was due to residual DMSO, which does not affect the next step.
- the piperidine adduct (62.1 g, 87 wt%, 54.0 g assay, 0.117 mol) was slurried in IPA/water (98:2, 365 mL). TFA (26.7 g, 18.0 mL, 0.234 mol) was added over 10 minutes maintaining the temperature at 20-25 °C. The triazole aldehyde was liberated during the pH adjustment. The product crystallized from the reaction mixture.
- the slurry was stirred for 2 hours at room temperature.
- the triazole- aldehyde was filtered, washed with IPA (40 mL) and dried at 40 °C under vacuum with a nitrogen stream for 16 hours to afford 30.5 g of pure product (>99.9 A%, >99.5 wt%) as a white crystalline solid.
- the isolated yield was 63% based on 1- dimethylamino-2-propyne and 65.5% based on sodium azide.
- the resulting solution / suspension was aged at 25 °C for 5 hours and the reaction was completed when starting material secondary amine was less than 0.1 A% (at 220 nm) as judged by LC.
- 2 eq. of IN HCl (2L, 2 mol) was added and the reaction mixture was aged for 4 hours (to break some boron complexes).
- Aqueous HCl (1.33 L, 3 N, 4 mol) was then added (maintaining 40 °C with cooling during HCl charge) and aged for 2 hours at 40 °C (to destroy some excess sodium triacetoxyborohydride and to break some boron complexes).
- reaction conditions other than the particular conditions as set forth herein above may be applicable as a consequence of variations in the reagents or methodology to prepare the compounds from the processes of the invention indicated above.
- specific reactivity of starting materials may vary according to and depending upon the particular substituents present or the conditions of manufacture, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be inte ⁇ reted as broadly as is reasonable.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002348526A CA2348526A1 (en) | 1998-10-30 | 1999-10-26 | Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine |
AU12330/00A AU1233000A (en) | 1998-10-30 | 1999-10-26 | Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine |
EP99971422A EP1124826A1 (en) | 1998-10-30 | 1999-10-26 | Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine |
JP2000579603A JP2002528546A (en) | 1998-10-30 | 1999-10-26 | 2- (R)-(1- (R)-(3,5-bis (trifluoromethyl) phenyl) ethoxy-4-((5-dimethylaminomethyl) -1,2,3-triazol-4-yl ) Method for producing methyl) -3- (S)-(4-fluorophenyl) morpholine compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10629198P | 1998-10-30 | 1998-10-30 | |
US60/106,291 | 1998-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000026215A1 true WO2000026215A1 (en) | 2000-05-11 |
Family
ID=22310624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/025080 WO2000026215A1 (en) | 1998-10-30 | 1999-10-26 | Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine |
Country Status (6)
Country | Link |
---|---|
US (1) | US6051717A (en) |
EP (1) | EP1124826A1 (en) |
JP (1) | JP2002528546A (en) |
AU (1) | AU1233000A (en) |
CA (1) | CA2348526A1 (en) |
WO (1) | WO2000026215A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030284A1 (en) | 2000-06-08 | 2003-08-20 | Merck & Co Inc | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALFA-R, 3A) -2- [1- (3,5-BIS (TRIFLUOROMETIL) PHENYL) ETOXI] -3- (4-FLUOROPHENIL) -1,4-OXAZINE; SUCH COMPOUND AND ITS POLYMORPHIC FORMS |
AU2006274051B2 (en) * | 2005-07-25 | 2012-03-22 | F. Hoffmann-La Roche Ag | Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
-
1999
- 1999-10-26 CA CA002348526A patent/CA2348526A1/en not_active Abandoned
- 1999-10-26 WO PCT/US1999/025080 patent/WO2000026215A1/en not_active Application Discontinuation
- 1999-10-26 JP JP2000579603A patent/JP2002528546A/en not_active Withdrawn
- 1999-10-26 EP EP99971422A patent/EP1124826A1/en not_active Withdrawn
- 1999-10-26 AU AU12330/00A patent/AU1233000A/en not_active Abandoned
- 1999-10-28 US US09/428,783 patent/US6051717A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
Non-Patent Citations (1)
Title |
---|
NAITO R ET AL: "Selective Muscarinic Antagonists. I. Synthesis and Antimuscarinic Properties of 4-Piperidyl Benzhydrylcarbamate Derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 46, no. 8, August 1998 (1998-08-01), PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP, pages 1274 - 1285, XP002127947, ISSN: 0009-2363 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
Also Published As
Publication number | Publication date |
---|---|
CA2348526A1 (en) | 2000-05-11 |
US6051717A (en) | 2000-04-18 |
JP2002528546A (en) | 2002-09-03 |
AU1233000A (en) | 2000-05-22 |
EP1124826A1 (en) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI663160B (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
CN112638869A (en) | Salt of methyl 6- (2, 4-dichlorophenyl) -5- [4- [ (3S) -1- (3-fluoropropyl) pyrrolidin-3-yl ] oxyphenyl ] -8, 9-dihydro-7H-benzo [7] annulene-2-carboxylate and process for preparing same | |
CN108203404A (en) | (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani | |
US7361756B2 (en) | Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril | |
JP2012508248A (en) | Method for synthesizing benzoacepine derivatives | |
CA2928242A1 (en) | Process for the preparation of a pde4 inhibitor | |
DK2635586T3 (en) | PROCEDURE FOR THE PREPARATION OF NALTREXON | |
EP3309158B1 (en) | Crystalline form k of rivaroxaban and process for its preparation | |
JP2024069193A (en) | Methods for the synthesis of bromodomain inhibitors | |
JP2023548666A (en) | 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene-7 Method of preparing -yl)oxy)-benzonitrile | |
US6051717A (en) | Convergent process for the preparation of a morpholine compound | |
KR101935636B1 (en) | A method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrocholoride | |
US7473805B2 (en) | Process for obtaining tolterodine | |
CN110818678B (en) | Method for preparing cyclohexane derivative | |
CN114026095A (en) | Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl ] methyl ] -3-oxo-5, 6,8,8 a-tetrahydro-1H-imidazo [1,5-a ] pyrazin-2-yl ] -carboxylic acid | |
WO2000026214A1 (en) | Linear process for the preparation of a morpholine compound | |
CN109970673B (en) | Preparation method of parecoxib sodium impurity | |
US11286254B2 (en) | Process for the synthesis of 2-benzhydryl-3 quinuclidinone | |
CN111100112B (en) | Benzothiophene derivative and process for producing the same | |
WO2006022488A1 (en) | Process for purification of cilostazol | |
WO2022082337A1 (en) | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile | |
EP3947348A1 (en) | Process for making siponimod and intermediate thereof | |
EP2989099A1 (en) | A process for the synthesis of maraviroc | |
JPH04273872A (en) | Novel diketeneimine derivative and preparation of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 12330 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999971422 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 579603 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2348526 Country of ref document: CA Ref country code: CA Ref document number: 2348526 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12330/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971422 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999971422 Country of ref document: EP |